Venturi Wealth Management LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Venturi Wealth Management LLC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 58.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,373 shares of the company’s stock after buying an additional 504 shares during the period. Venturi Wealth Management LLC’s holdings in TransMedics Group were worth $86,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the business. Principal Financial Group Inc. lifted its stake in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Public Sector Pension Investment Board acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $11,079,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after buying an additional 64,872 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its stake in TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after acquiring an additional 64,360 shares in the last quarter. Finally, WCM Investment Management LLC purchased a new stake in TransMedics Group in the third quarter valued at $8,720,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 4.6 %

Shares of TMDX stock opened at $71.95 on Monday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The business’s fifty day moving average price is $66.63 and its 200 day moving average price is $104.16. The firm has a market capitalization of $2.41 billion, a PE ratio of 76.54 and a beta of 2.12.

Analyst Ratings Changes

Several equities analysts have issued reports on TMDX shares. TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.70.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.